DePinho and colleagues found that ENO1 was often deleted in glioblastomas and rendered glioma cells more sensitive to the inhibition of ENO2, herein proposed collateral damage caused by passenger deletions of redundant essential genes as a novel therapeutic strategy (71). The gene discussed is ENO1; the disease is glioblastoma.